Cointime

EditForce

company

About

EditForce develops drugs and seeds by using nucleic acid manipulation technologies.

Highlights

Total Funding Amount
¥1.84B
Funding Rounds
3
Investors
8
Employee Profiles
10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
¥800M
Industries
Biotechnology,Medical,Nursing and Residential Care
Founded date
May 15, 2015
Number Of Employee
11 - 50
Operating Status
Active
Legal Name
EditForce Inc., Edit Force Co., Ltd.

EditForce develops drugs and seeds by using nucleic acid (DNA/RNA) manipulation technologies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
¥1.84B
EditForce has raised a total of ¥1.84B in funding over 2 rounds. Their latest funding was raised on May 26, 2021 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 26, 2021 Series Unknown ¥800M 4 Newton Biocapital — Detail
Mar 1, 2019 Series B ¥870M 6 — — Detail
Feb 3, 2016 Seed ¥175M 2 UTEC - The University of Tokyo Edge Capital Partners — Detail

Investors

Number of Lead Investors
Number of Investors
2
8
EditForce is funded by 8 investors. Newton Biocapital and Global Brain Corporation are the most recent investors.
Investor Name Lead Investor Funding Round
Newton Biocapital Yes Series Unknown
Global Brain Corporation — Series Unknown
ITOCHU Technology Ventures — Series Unknown
UTEC - The University of Tokyo Edge Capital Partners — Series Unknown
Japan Science and Technology Agency — Series B
K4 Ventures — Series B
QB Capital — Series B
KISCO — Seed

Employee Profiles

Number of Employee Profiles
10
EditForce has 10 current employee profiles, including Board member Tomotaka Goji
Tomotaka Goji
Board member
Atsushi Usami
Board member
Takahiro Nakamura
Executive
Koji Abe
Board member
Show More
Cointime
Content
Company